Perspectives on the prevention and treatment of infection for orthopedic tissue engineering applications

Shah, Sarita R.; Kasper, F. Kurtis; Mikos, Antonios G.

doi:10.1007/s11434-013-5780-8

Cited by 25 publications

(21 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibiotics are another example of chemical cues often delivered in conjunction with tissue engineering strategies. In an infected orthopaedic defect, encapsulating antibiotics for local drug delivery into the scaffold may be required to stimulate healing 28 . Mechanical cues have long been used to stimulate bone formation, such as in distraction osteogenesis.…”

Section: Signalsmentioning

confidence: 99%

Tissue Engineering in Orthopaedics

Tatara

Mikos

2016

The Journal of Bone and Joint Surgery

Self Cite

View full text Add to dashboard Cite

Section: Signalsmentioning

confidence: 99%

Tissue Engineering in Orthopaedics

Tatara

Mikos

2016

The Journal of Bone and Joint Surgery

Self Cite

View full text Add to dashboard Cite

“…Treatment of bone infections in patients with fractures can involve operative débridement of necrotic bone followed by several weeks of systemic antibiotics, temporary fixation, and/or implantation of devices to promote bone regeneration [11,44]. For orthopaedic infections, Staphylococcus aureus is the most commonly isolated agent, accounting for more than 1 . 2 of all infections [28].…”

Section: Introductionmentioning

confidence: 99%

“…For orthopaedic infections, Staphylococcus aureus is the most commonly isolated agent, accounting for more than 1 . 2 of all infections [28]. In addition to increasing trends of antimicrobial resistance, the ability of bacteria to develop and persist in biofilms on implanted biomedical devices is recognized as a major factor contributing to chronic relapsing infections and nonosseous union [4,35,42,44,48,49].…”

Section: Introductionmentioning

confidence: 99%

“…Bacterial biofilms are a protected mode of growth characterized by a high tolerance to the activity of antimicrobials compared with planktonic bacteria, which is partly attributable to the limited permeability of antimicrobials through the extracellular matrix surrounding the bacteria and the reduced metabolic state of the persister cells in the biofilm [11,28,44,50]. Although clinical studies have underscored the relationship between infection and nonunion of diaphyseal fractures [24], periarticular fractures also have high rates of infections complications.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, inhibiting the formation of a biofilm may be an alternative strategy for reducing the incidence of infectious complications and nonunions. Several reviews have highlighted the need for biomaterials that deter establishment of an infection by concurrently inhibiting biofilm formation and promoting tissue integration and regeneration [44,45,53]. The Disomers of amino acids (D-AAs) prevent and disperse biofilms formed by a broad range of bacterial species, including S aureus [23,26], by inhibiting initial bacterial attachment to surfaces [55], inhibiting localization of cellcell adhesion proteins at the cell surface [23,26], inhibiting expression of biofilm matrix genes [27], and promoting release of amyloid fibers from the cell wall [26].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

d-amino Acid Inhibits Biofilm but not New Bone Formation in an Ovine Model

Harmata

Sánchez

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Infectious complications of musculoskeletal trauma are an important factor contributing to patient morbidity. Biofilm-dispersive bone grafts augmented with D-amino acids (D-AAs) prevent biofilm formation in vitro and in vivo, but the effects of D-AAs on osteocompatibility and new bone formation have not been investigated.Questions/purposes We asked: (1) Do D-AAs hinder osteoblast and osteoclast differentiation in vitro? (2) Does local delivery of D-AAs from low-viscosity bone grafts inhibit new bone formation in a large-animal model? Methods Methicillin-sensitive Staphylococcus aureus and methicillin-resistant S aureus clinical isolates, mouse bone marrow stromal cells, and osteoclast precursor cells were treated with an equal mass (1:1:1) mixture of D-Pro:DMet:D-Phe. The effects of the D-AA dose on biofilm inhibition (n = 4), biofilm dispersion (n = 4), and bone marrow stromal cell proliferation (n = 3) were quantitatively measured by crystal violet staining. Osteoblast differentiation was quantitatively assessed by alkaline phosphatase staining, von Kossa staining, and quantitative reverse transcription for the osteogenic factors a1Col1 and Ocn (n = 3). Osteoclast differentiation was quantitatively measured by tartrate-resistant acid phosphatase staining (n = 3). Bone grafts augmented with 0 or 200 mmol/L D-AAs were injected in ovine femoral condyle defects in four sheep. New bone formation was evaluated by lCT and histology 4 months later. An a priori power analysis indicated that a sample size of four would detect a 7.5% difference of bone volume/total volume between groups assuming a mean and SD of 30% and 5%, respectively, with a power of 80% and an alpha level of 0.05 using a two-tailed t-test between the means of two independent samples. Results Bone marrow stromal cell proliferation, osteoblast differentiation, and osteoclast differentiation were inhibited at D-AAs concentrations of 27 mmol/L or greater in a dose-responsive manner in vitro (p \ 0.05). InThe institution of one or more of the authors (SAG, FE, JCW) has received, during the study period, funding from the Orthopaedic Extremity Trauma Research Program (SAG and JCW), the National Institute of Arthritis and Musculoskeletal Diseases (SAG, JCW, and FE), Medtronic, Inc (SAG); Oak Ridge Institute (AJH); and the National Institutes of Health (SAG). One of the authors certifies that he (SAG), or a member of his or her immediate family, has or may receive payments or benefits, during the study period, an amount less than USD 10,000, from Medtronic Spine and Biologics (Memphis, TN, USA).

show abstract

L‐arginine and quaternary ammonium salt‐synergistically modified waterborne polyurethane for efficient antibacterial performance

Qian²,

Wang

et al. 2023

J of Applied Polymer Sci

View full text Add to dashboard Cite

Antibacterial waterborne polyurethane (WPU) is attracting increasing interest in a wide range of industrial applications due to its versatility and eco‐friendliness. However, single system antimicrobial WPU often does not meet the requirements of highly antimicrobial coating fields. Therefore, WPU was synergistically modified by L‐arginine (L‐Arg) and quaternary ammonium salts (QAs) in this study. They were introduced into the molecular structure of WPU by in‐situ emulsion polymerization to form the composite antibacterial system (WRPUs). The results showed that the composite systems had excellent antibacterial activity against both Escherichia coli and Staphylococcus aureus compared to single system. When the content of both L‐Arg and QAs was 7%, the antibacterial effect of WRPU7 was optimal, from the sum (E. coli: and S. aureus: ) of the inhibition circles of L‐Arg and QAs to 21.4 and 22.6 mm, respectively, net efficiency increase of 29% and 17%, fully reflecting the synergistic effect of Taken together, the results presented in this study confirm the significance of L‐Arg and QAs as synergistic antimicrobial building blocks. In this way, the antimicrobial performance of WPU can be significantly improved and better biocompatibility can be exhibited, thus broadening the application of WPU in highly antibacterial fields.

show abstract

Perspectives on the prevention and treatment of infection for orthopedic tissue engineering applications

Cited by 25 publications

References 63 publications

Tissue Engineering in Orthopaedics

Tissue Engineering in Orthopaedics

d-amino Acid Inhibits Biofilm but not New Bone Formation in an Ovine Model

L‐arginine and quaternary ammonium salt‐synergistically modified waterborne polyurethane for efficient antibacterial performance

Contact Info

Product

Resources

About